<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.4168/aair.2017.9.3.191</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:33029887">http://nrs.harvard.edu/urn-3:HUL.InstRepos:33029887</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Genetic Signatures of Asthma Exacerbation

Heung-Woo Park,1,2 Kelan G. Tantisira2,3,*

1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
2The Channing Division of Network Medicine, Department of Medicine, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA, USA
3Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA

INTRODUCTION

Asthma exacerbation (AE) usually denotes worsening of asthma symptoms that requires intense management to prevent further deterioration. AE has been reported to correlate with clinical and demographic factors, such as race, gender, and treatment compliance as well as environmental factors, such as viral infection, smoking, and air pollution. In addition, recent observations suggest that there are likely to be genetic factors specific to AE. Understanding genetic factors specific to AE is essential to develop therapy tailored for exacerbation-prone asthma. Here, we summarize the results of studies involving genetic risk factors for AE. To simplify and enhance understanding, we reviewed the studies according to the following categories: hypothesis-driven approaches, hypothesis-free approaches, gene-environment interactions, and pharmacogenetics.

Key Words: Asthma exacerbation; genetics; gene-environment interaction; genome-wide association study; pharmacogenetics

Asthma is a chronic inflammatory disorder characterized by variable airway obstruction. Occasionally, patients with asthma experience sudden deteriorations of their symptoms which are referred to as an ‘exacerbation.’ Although there are diverse viewpoints, asthma exacerbation usually denotes worsening of asthma symptoms that requires intense management to prevent further deterioration. For instance, in the National Institute of Health-sponsored Asthma Outcomes workshop, asthma exacerbation was defined as worsening of asthma requiring the use of systemic corticosteroids to prevent a serious outcome.1 Exacerbations have been reported to correlate with clinical and demographic factors, such as race, gender, and treatment compliance as well as environmental factors, such as viral infection, smoking and air pollution.2-8 To reduce the risk of asthma exacerbation (AE), a tailored application of standard treatment based on detailed phenotyping was proposed.9

A complex interaction between genetic and nongenetic factors has been thought to be important in asthma pathogenesis. Thus, it is not surprising that heritability estimates have indicated that, on average, genetic variation among individuals accounts for one-half of the risk of asthma.10 Interestingly, recent observations show that genetic risk factors important in asthma progression and severity differ from those that determine susceptibility,11 which suggests that there must be genetic factors specific to AE. For example, genetic predictors of a poor long-term response to inhaled corticosteroids (ICSs) markedly differ according to outcomes (exacerbations vs lung function) in childhood asthmatics.12 Understanding genetic factors specific to AE is essential to develop specific therapy tailored for exacerbation-prone asthma. With this in mind, we aimed to summarize genetic association studies mainly focused on AE in this review. Here, a severe AE represents acute symptoms requiring emergency department visit, hospitalization, and intubation; a less severe AE represents acute symptoms requiring treatment with an oral or parenteral corticosteroid. To simplify and enhance understanding, we reviewed the studies according to the following categories: hypothesis-driven or candidate gene approaches, hypothesis-free or genome-wide approaches, gene-environment interactions, and pharmacogenetics.

Studies with a hypothesis-driven approach

Although asthma is currently believed to be a heterogeneous disease, an allergic asthma characterized by Th2-type T cells, IgE, eosinophils, mast cells, and cytokines is a traditional concept in terms of immunopathology.13 The early and pioneering

*Correspondence to: Kelan G. Tantisira, MD, M.PH., Channing Division of Network Medicine, Brigham & Women’s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA.
Tel: +617-525-0863; Fax: +617-525-0558; E-mail: rekgt@channing.harvard.edu
Received: July 20, 2016; Revised: October 14, 2016; Accepted: October 18, 2016

http://e-aair.org
studies driven by \textit{a priori} hypothesis focused on this Th2 asthma phenotype. A previous report using a murine model of asthma showed that IL-13 is a critical cytokine in the development of asthma.\textsuperscript{14} For this reason, genes related to the IL-13 signaling pathway have been frequent targets of asthma genetic studies. Hunninghake \textit{et al.}\textsuperscript{15} reported that rs1800925, a functional single nucleotide polymorphism (SNP) located at the promoter area of IL-13, is associated with the risk of severe AEs among Costa Rican and non-Hispanic children with asthma. Both IL-13 and IL-4 signals act via the common IL-4 receptor alpha (IL-4R\textalpha{}).\textsuperscript{16} In 2 well-characterized cohorts of severe asthmatics, 2 non-synonymous coding SNPs (rs1805011 [E375A] and rs1801275 [Q551R]) were associated with AE requiring an intensive care unit stay or intubation in addition to lower lung function and mast cell-related tissue inflammation.\textsuperscript{17}

The gene \textit{CHI3L1} coding for the protein chitinase 3-like-1 (CHI3L1) is reported to be a susceptibility gene for asthma\textsuperscript{18} and \textit{CHI3L1} is thought to be a possible biomarker for asthma and decline in lung function. Based on this finding, a cross-sectional survey of 1,071 children and young adults with asthma (aged 3 to 22 years) was performed in Scotland.\textsuperscript{19} They showed that rs4950928 which is associated with \textit{CHI3L1} levels significantly increases the risk of severe AEs.\textsuperscript{19} However, in this study, investigators could not find any significant association between this SNP and less severe AEs defined as oral steroid intake at investigators could not find any significant association between this SNP and less severe AEs defined as oral steroid intake at

\textbf{Studies with a hypothesis-free approach}

A hypothesis-free approach means a genome screening without any preexisting predilection for specific areas, genes, or variants\textsuperscript{22} and has provided a comprehensive description of the genetic causes of complex disease. A recent GWAS performed in childhood asthmatics in Denmark has identified 5 loci with genome-wide significances associated with severe AEs occurring between 2 and 6 years.\textsuperscript{23} Among those 5 loci, \textit{CDHR3} (encoding cadherin-related family member 3) was not previously reported as asthma susceptibility loci. Discovery of a new AE risk gene is partly attributable to the fact that this study focused on a specific asthma phenotype characterized by recurrent and severe AE, which implies the strength of applying specific phenotyping in asthma genetic studies. Another GWAS focusing on less severe AEs identified several variants in \textit{CTNNA3} and \textit{SEMA3D} as risk loci in 2 independent pediatric asthma clinical trials.\textsuperscript{24} Among them, rs10997296 in \textit{CTNNA3} locus with a genome-wide significance was associated with \textit{CTNNA3} mRNA expression in CD4+ cells from asthmatic patients and rs993312 in \textit{SEMA3D} locus replicated in a clinical biobank database of childhood and young adult asthmatics, though its significance did not reach a genome-wide significance in the primary analysis.\textsuperscript{24}

As mentioned before, complex and multiple traits are associated with AE. A lack of statistical power which comes from small effects of many causal factors, possible interactions among the causal factors, and small sample sizes is an important challenge for prediction of AE, a complex trait. Although overfit pitfalls exist, development of a predicting model using

\begin{table}[h]
\centering
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Definition of exacerbation} & \textbf{Gene} & \textbf{Associated variants} & \textbf{Reference Number} \\
\hline
ER visit or hospitalization & IL13 & rs1800925 & 15 \\
\hline
\thead{The mutant allele of rs1800925 was inversely associated with AEs in Costa Rican children with asthma (\textit{P} = 0.069). Although this SNP was not associated with AEs among all non-Hispanic white children, it was associated with increased risk of AEs among children on ICSs (\textit{P} = 0.02) in the CAMP trial.} & & & \\
\hline
ICU care, ER visit or hospitalization & IL4RA & rs1805011, rs1801275 & 17 \\
\hline
\thead{The mutant allele of rs1805011 [E375A] and rs1801275 [Q551R], which were more common in African Americans, was associated with a history of AEs in two cohorts of adult asthmatics enrolled in US.} & & & \\
\hline
Hospitalization & CHI3L1 & rs4950928 & 19 \\
\hline
\thead{The mutant allele of rs4950928 conferred protections against AEs (\textit{OR} = 0.62, 95\%\textit{CI}: 0.41-0.92, \textit{P} = 0.018) in children and young adults with asthma in Scotland.} & & & \\
\hline
Hospitalization, SA or OSB & ORMDL3 & rs7216389 & 21 \\
\hline
\thead{The SNP in ORMDL3 rs7216389 was genotyped in 376 children born to mothers with asthma and enrolled in the Copenhagen Prospective Study. This SNP was significantly associated with AEs (hazard ratio = 2.66, 95\%\textit{CI}: 1.98-4.48, \textit{P} = 0.0002). The increased risk of AEs persisted from 1 to 6 years of age.} & & & \\
\hline
\end{tabular}
\caption{Studies using a hypothesis-driven approach}
\end{table}

AE, Asthma exacerbation; CAMP, Childhood asthma management program; CI, Confidence interval; ER, Emergency room; ICU, Intensive care unit; ICS, Inhaled corticosteroid; OR, Odds ratio; OSB, Oral steroid burst; SA, School absence; SNP, Single nucleotide polymorphism.
data mining methods is a way to handle this type of problems. Random Forests (RF) are a classification algorithm that is composed of a set of random decision trees, and we can integrate hundreds of SNPs and clinical traits to predict complex clinical phenotypes by RF. Xu et al. performed a GWAS of severe AE in a pediatric asthma clinical trial and identified a list of top GWAS SNPs based on RF importance score. The authors predicted severe AEs using the top 10 to 320 SNPs together with age, sex, prebronchodilator FEV1 percentage predicted, and treatment group. With only 417 childhood asthmatics, using 160 SNPs, they could generate a good predictive model for severe AEs, with a >0.66 area under the curve and about 0.66 sensitivity and 0.6 specificity. A hypothesis-free approach can help us search unknown genetic markers associated with AEs. In addition, by using machine learning methods, we can increase our understanding of the basis for epistatic (gene-gene) interactions underlying AEs. The results of the studies using a hypothesis-free approach are summarized in Table 2.

**Gene-environment interactions**

In the study by Xu et al., using the clinical traits alone in the predictive model yielded an area under the curve of 0.54, which suggests that AE is affected by non-genetic as well as genetic factors. Among non-genetic factors, indoor and outdoor environment exposures pose an important influence on AE. A gene and environment interaction is defined as a different effect of a genotype on disease risk in persons with different environmental exposures. A search for genetic factors showing significant interactions with environmental exposures is clinically significant as environmental exposures may be modifiable. For indoor exposures, rs512625 in ADAM33 located in chromosome 20p13 showed significant interactive effects with environmental tobacco smoke on severe AE.

### Table 2. Studies with a hypothesis-free approach

<table>
<thead>
<tr>
<th>Definition of exacerbation</th>
<th>Gene</th>
<th>Associated variants</th>
<th>Reference Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospitalization</td>
<td>CDHR3</td>
<td>rs6967330</td>
<td>23</td>
</tr>
<tr>
<td># Investigators performed a GWAS of a specific asthma phenotype characterized by recurrent and severe exacerbations occurring between 2 and 6 years of age in Denmark. They identified five loci with genome-wide significant associations. The 4 genes GSDMB, IL33, RAD50, and IL1RL1, were previously reported as asthma susceptibility loci but CDHR3 was a new susceptibility gene.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSB</td>
<td>CTNNA3, SEMA3D</td>
<td>rs1099729, rs99331</td>
<td>24</td>
</tr>
<tr>
<td># A GWAS focusing less severe AEs identified several variants in CTNNA3 and SEMA3D as risk loci in two independent childhood asthma clinical trials in the US. Among them, rs1099729 in CTNNA3 locus with a genome-wide significance was associated with CTNNA3 mRNA expression in CD4+ cells from asthmatic patients and rs993312 in SEMA3D locus replicated in a clinical biobank database of childhood and young adult asthmatics, although its significance did not reach a genome-wide significance in the primary analysis.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER visit or hospitalization</td>
<td>NA</td>
<td>160 SNPs</td>
<td>28</td>
</tr>
<tr>
<td># Investigators performed a GWAS of severe AEs in a childhood asthma clinical trial in the US and identified a list of top GWAS SNPs based on Random Forest importance score. With only 417 childhood asthmatics, using 160 SNPs, age, sex, prebronchodilator FEV1 predicted percentage, and treatment group, they could generate a good predictive model for severe AEs, with a &gt;0.66 area under the curve and about 0.66 sensitivity and 0.6 specificity.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AE, Asthma exacerbation; ER, Emergency room; FEV1, Forced expiratory volume in 1 second; NA, Not applicable; OSB, Oral steroid burst; SNP, Single nucleotide polymorphism.
Taken together, genetic predispositions may play a role in virus-induced AE. In this respect, CDHR3 which was identified as a gene associated with AE in a recent GWAS is of particular interest. CDHR3 is a transmembrane protein and highly expressed in the human lung and airway epithelium. Recently, it was reported that CDHR3 acts as a rhinovirus C receptor. In addition, introduction of the risk variant of rs6967330 in CDHR3 resulted in 10-fold enhanced rhinovirus C binding. These findings suggest that CDHR3 variants may confer risk to severe AE via an interaction with rhinovirus C infection. These findings may also explain why CDHR3 was not previously reported as asthma susceptibility loci and has now been identified only in a GWAS focusing on a specific phenotype, severe AE. A hypothesis-free approach is also applicable to the gene and environment interaction analysis. Du et al. conducted a GWAS of gene-vitamin D interaction on AEs in participants in the Childhood Asthma Management Program. They identified 3 common variants in the class I MHC-restricted T cell–associated molecule gene (CRTAM) that were associated with an increased rate of AEs in subjects with a low circulating vitamin D level. Results were replicated in a second independent Costa Rican cohort. As genome-wide gene-environment interaction analyses are often underpowered after adjustment for multiple comparisons, Sordillo et al. utilized differential gene expression in response to the environmental exposure to capture the most relevant genes. The top differentially expressed genes, IL9, IL5, and PRG2 (proteoglycan 2), were identified through comparison genome-wise gene expression on PBMCs from childhood asthmatics between pre- and post-stimulation of dust mite allergen (Der f 1) for 72 hours. They then evaluated whether the 3 genes showed significant interactive effects with home Der p 1 allergen levels on severe AEs in 2 independent cohorts of childhood asthmatics. They found that subjects with the dominant genotype for these IL9 polymorphisms (rs11741137, rs2069885, and rs1859430) were more likely to report a severe AE if exposed to increased dust mite levels. The results of the studies showing gene-environment interactions are summarized in Table 3.

Table 3. Studies showing gene-environment interactions

<table>
<thead>
<tr>
<th>Definition of exacerbation</th>
<th>Gene</th>
<th>Associated variants</th>
<th>Environment</th>
<th>Reference Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate exacerbation*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| # Investigators conducted a genome-wide study of gene-vitamin D interaction on AEs using population-based and family-based approaches on 403 subjects and 7 from the CAMP trial. Vitamin D levels were obtained at the time of randomization and were dichotomized as low (≤30 mg/mL) or high (>30 mg/mL). Three common variants in the CRTAM were associated with an increased rate of SEs based on the presence of a low circulating vitamin D level. These results were replicated in a second independent population from Costa Rica.
| Moderate exacerbation*    |      |                     |             |                  |
| # Investigators followed exacerbation-prone childhood asthmatics prospectively and evaluated differential gene expressions in nasal lavage samples obtained during an acute, moderate, picornavirus-induced exacerbation, and 7 to 14 days later. They found that more than 1,000 genes was upregulated during AEs in comparison with 7 to 14 days later and revealed that interferon regulatory factor 7 was one of the hyperconnected hub nodes using coexpression network analysis.
| Hospitalization            |      |                     |             |                  |
| # In this case-control study, 423 asthmatic children and 414 non-asthmatic controls (age 5-18 yr) were recruited in Croatia. Early-life environmental tobacco smoke exposure was assessed by questionnaire. For rs512625 in ADAM33, there was significant interaction with environmental tobacco smoke exposure in relation to hospitalizations (Pinteraction = 0.02).
| Hospitalization            |      |                     |             |                  |
| # In this case-control study, 417 asthmatic children and 407 non-asthmatic controls (age 5-18 yr) were recruited in Croatia. Endotoxin exposure was measured in dust samples collected from homes. CD14 SNPs rs5744455 (FDR P = 0.02) and LY96 SNPs rs17226666 (FDR P = 0.04) were significantly associated with AEs.
| Hospitalization            |      |                     |             |                  |
| # The association between 9 SNPs in TGFBI and AE was tested in 2 cohorts; 416 Costa Rican parent-child trios and 465 families of non-Hispanic white children in the CAMP trial. Exposure to dust mite allergen (Der p 1 level) was dichotomized at 10 mg/g or greater. Dust mite exposure significantly modified the effect of the A allele of the promoter SNP rs2241712 on AEs in both cohorts (Pinteraction = 0.008 in Costa Rica and Pinteraction = 0.03 in CAMP).
| Hospitalization            |      |                     |             |                  |
| # Investigators used differential genome-wide expression profiles from a longitudinal birth cohort study in response to Der f 1 allergen (sensitized vs nonsensitized) to inform a gene-environment study of dust mite exposure and asthma severity. Home dust mite allergen levels (<10 or ≥10 mg/g dust) were assessed at baseline. IL9 polymorphisms (rs11741137, rs2069885, and rs1859430) showed evidence for interaction with dust mite in the CAMP trial (Pinteraction = 0.02 to 0.03), with replication in the Costa Rica Study (Pinteraction = 0.04).
| Hospitalization            |      |                     |             |                  |

* Lack of symptom relief after 3 treatments, low peak flow readings (<80% of personal best), or both.

AE, Asthma exacerbation; ER, Emergency room; FDR, False discovery rate; NA, Not applicable; SNP, Single nucleotide polymorphism.
Pharmacogenetics

The current primary therapies for asthma are focused on increasing bronchial smooth muscle relaxation (bronchodilation) and decreasing airway inflammation. The response to drug treatment in asthma is a complex trait and markedly variable even in patients with apparently similar clinical features.\(^{45}\) In asthma, a poor response to drug treatment is related to AEs.\(^{46}\) Pharmacogenetics is usually defined as a study of variations of DNA characteristics as related to drug response.\(^{44}\) AE is one of the important target phenotypes in pharmacogenetic studies of asthma. Inhaled \(\beta_2\)-agonists are widely used in asthma treatment for the purpose of bronchodilation and act via their binding to the \(\beta_2\) adrenergic receptor (\(\beta_2\)-AR). The effect of genetic variants in the \(ADRB2\) coding \(\beta_2\)-AR on receptor function has been intensively examined.\(^{45,46}\) For this reason, pharmacogenetics studies on heterogeneity in response to inhaled \(\beta_2\)-agonists have mostly focused on \(ADRB2\). A recent meta-analysis stratified by treatment showed that the use of a long acting \(\beta_2\)-agonist (LABA), but not a leukotriene receptor antagonist, as an add-on controller is associated with increased risk of AE in children carrying 1 or 2 A alleles at rs1042713 (Arg16 amino acid) in \(ADRB2\).\(^{47}\) In this study, data from 4,226 children of white Northern European and Latino origin was analyzed, and both severe and non-severe AEs were included. However, a

Table 4. Pharmacogenetic studies

<table>
<thead>
<tr>
<th>Definition of exacerbation</th>
<th>Gene</th>
<th>Associated variants</th>
<th>Reference Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>ER visit, hospitalization, or OSB</td>
<td>ADRB2</td>
<td>rs1042713</td>
<td>47</td>
</tr>
<tr>
<td># Data from 4,226 children of white Northern European and Latino origin were analyzed, and the OR for AE increased by 1.52 (95% CI = 1.17-1.99, (P = 0.0021)) for each copy of the mutant allele of rs1042713 among the children treated with ICSS plus LABAs but not for treatment with ICSS alone or ICSS plus LTRAs or ICSS plus LABAs plusLTRAs.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER visit, hospitalization, or OSB</td>
<td>ADRB2</td>
<td>rs1042713</td>
<td>48</td>
</tr>
<tr>
<td># This pharmacogenetic analyses of two randomized studies to assess ICA plus LABA on AE showed that genotypes of rs1042713 had no effect on the percentage of adult asthmatics with severe AEs across all treatment groups</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER visit, or hospitalization</td>
<td>FCER2</td>
<td>rs28364072</td>
<td>50</td>
</tr>
<tr>
<td># This study demonstrated associations between rs28364072 in FCER2 and severe AEs in 311 white and African American children enrolled in the CAMP trial (hazard ratio = 3.95, 95% CI = 1.64-9.51 and hazard ratio = 3.08, 95%CI = 1.00-9.47, respectively), despite ICS use.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER visit, hospitalization, or OSB</td>
<td>FCER2</td>
<td>rs28364072</td>
<td>51</td>
</tr>
<tr>
<td># This study analyzed data from 2 populations of childhood asthmatics in Europe using ICS. This report showed that rs28364072 in FCER2 was associated with increased risk of severe AEs (OR = 1.91, 95%CI = 1.06-3.40).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER visit, hospitalization, or OSB</td>
<td>ST13</td>
<td>rs138335</td>
<td>52</td>
</tr>
<tr>
<td># This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to AEs in children and young adults treated with ICS. It was a meta-analysis of three cohort studies in the UK and Netherlands. They found that rs138335 in ST13 was associated with an increased risk of hospitalization and OSB in the previous year (OR = 1.22, (P = 0.013) and OR = 1.22, (P = 0.0017), respectively). This association was replicated in the 3 independent cohorts in the US and the UK.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSB</td>
<td>P2RX7</td>
<td>rs2230911</td>
<td>53</td>
</tr>
<tr>
<td># A matched P2RX7 genetic case-control study was performed with samples from adult participants enrolled in the Asthma Clinical Research Network trial. African American carriers of the mutant allele of the rs2230911 (loss-of-function SNP) were more likely to have a history of OSB in the previous 12 months, with adjustment for ICS and LABA (OR = 2.7, 95%CI = 1.2-6.2, (P = 0.018)).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER visit, hospitalization, or OSB</td>
<td>CMTR1</td>
<td>rs2395672</td>
<td>54</td>
</tr>
<tr>
<td># This is a GWAS of 237,726 common, independent markers was conducted in 806 Caucasian asthmatic patients from 2 population-based biobanks in US (both children and adult were included). Rs2395672 in CMTR1, was associated with an increased risk of AEs in both populations (OR = 1.07, 95%CI = 1.03-1.11, joint (P = 2.3\times 10^{06})).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER visit, hospitalization, or OSB</td>
<td>LTC4S, LTA4H</td>
<td>rs730012, rs2660845</td>
<td>55</td>
</tr>
<tr>
<td># This is a prospective pharmacogenetic study to compare the efficacy of theophylline and montelukast as an add-on therapy in adult asthmatics in the US. Heterozygotes of rs730012 in LTC4s receiving montelukast had a 76% reduced risk of having an AE compared with reference allele homozygotes ((P = 0.023)). For rs2660845 in LTA4H, the risk of having at least 1 AE was 4- to 4.5-fold higher in heterozygotes and mutant allele homozygotes compared with reference allele homozygotes.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER visit, hospitalization, or OSB</td>
<td>IL4RA</td>
<td>rs8832</td>
<td>58</td>
</tr>
<tr>
<td># This is a pharmacogenetic analysis performed in a phase 2b clinical trial of pitrakinra, an IL-4Ra antagonist. A total of 407 non-Hispanic white adult asthmatics were enrolled, and 21 tagging and nonsynonymous SNPs in IL4Ra were genotyped. Subjects homozygous for the rs8832 common alleles randomized to pitrakinra (placebo group nonsignificant) had decreased AEs. There was also a significant pitrakinra dose-response relationship for AEs in subjects homozygous for the common allele in rs8832 ((P = 0.009)).</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AE, Asthma exacerbation; CAMP, Childhood asthma management program; CI, Confidence interval; ER, Emergency room; ICS, Inhaled corticosteroid; LABA, Long acting \(\beta_2\)-agonist; LTRA, Leukotriene receptor antagonist; OR, Odds ratio; OSB, Oral steroid burst; SNP, Single nucleotide polymorphism.
Figure. Summary of plausible biological mechanisms underlying genes associated with asthma exacerbation. (A) Genes related with gene-environment interactions and asthma pathogenesis. (B) Genes related with pharmacogenetic effects. β2-AR, β2-adrenergic receptors; CysLTR1, cysteinyl leukotriene receptor 1; GC, glucocorticoid; GR, glucocorticoid receptor; LTC4, leukotriene C4.
pharmacogenetic analysis of 2 prospective clinical trials undertaken in adult asthmatics showed no effect of ADRB2 variation, including rs1042713, on severe AE when they were treated with LABA plus (ICS). This difference suggests that there might be a specific genetic mechanism regulating AE in response to a LABA in children that does not carry over to adults. Although ICS is the mainstay of asthma treatment, individual responses vary widely and some asthmatics experience exacerbations while on ICS. The SNP in FCER2 (T2206C) rs28364072 was reported to be associated with severe AEs in both white and African American children with asthma enrolled in the CAMP trial. This strong association demonstrated an almost 4-fold increased risk of exacerbations for subjects homozygous for the mutant allele and was replicated in asthmatic children of European origin. Two SNPs in ST13 (rs138335 and rs138337), coding for a co-chaperone of the glucocorticoid receptor, were associated with AEs in the previous year in asthmatic children and young adults despite their ICS use. In addition, P2RX7 were identified as a gene associated with AEs in patients taking ICS via a hypothesis-driven approach. A GWAS of 237,726 common, independent markers which was conducted in 806 Caucasian asthmatic patients revealed that 6 novel SNPs associated with differential risk of severe AEs. Among them, 2 SNPs (rs2395672 in CMTR1 and rs279728) were associated with increased risk of AEs, while 4 SNPs (rs4271056, rs6467778, rs2691529, and rs9303988) were associated with decreased risk of AEs. Two SNPs (rs730012 in LTRAS and rs2660845 in LTA4H) were reported to be associated with AEs in adult asthmatics treated by montelukast for 6 months. Currently, biological drugs targeting specific cytokines are under active development with a hope that these drugs would be helpful for severe asthmatics with frequent AEs. Pitirakirina, which acts as an antagonist at the heterodimeric receptor complex (IL-4Rα/IL-13Rα) shared by both IL-4 and IL-13, is a good example. Interestingly, it is reported that pitirakirina shows a dose-response relationship for AEs according to the genotype of SNPs that tagged blocks of correlated IL4RA polymorphisms in non-Hispanic white adults with asthma. All these findings clearly suggest that pharmacogenetics may be useful to identify an asthma subgroup that is more responsive to therapy and thus reduce the possibility of AEs. The results of pharmacogenetic studies are summarized in Table 4.

CONCLUSIONS

The goal of asthma treatment is to prevent recurrent exacerbations. However, we do not have reliable biomarkers predicting in what patient and when AEs will occur. A search for such biomarkers is very important in that new therapies that exhibit relatively selective benefits in reducing AEs become available. Accumulated evidence now suggests the potential role of genetic variants in determining the risk for AE. Figure summarizes plausible biological mechanisms underlying genes associated with asthma exacerbation. However, genetic factors associated with susceptibility to asthma and those associated with frequency of AEs are often inseparably related. Thus, it is possible that some genes listed here could be rather specific to particular endotypes into asthma which are prone to frequent AE. Future investigations of the effects of genetic variants upon AE should consider the interactions of genes with race/ethnicity, medication use, and atopic status as well as previously reported environmental factors. In addition, integrated approaches based on recent advances in omics technology need to be utilized in future study on the association between genes and AEs.

REFERENCES

5. Busse WW, Lemanske RF Jr, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 2010;376:826-34.


